MRKMerck & Co.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though at the top of its own P/E range.
Priced for ~7% a year FCF growth. Roughly in line with its three-year revenue growth of 5% a year.
Expensive vs its own history: P/E 115.3 vs a 22.4 median over 40 quarters (+415% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What MRK's price assumes
Merck & Co. trades at 115× earnings against 40.0× for the median Drug Manufacturers - General name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - General median 40.0 · 2.88× the median: the market pays up for this one
- Price / sales
- 5.38
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 4.5%
Free cash flow yield · Drug Manufacturers - General median 5.5%
- Growth the price implies
- +7.1%
Growth the price implies · The price pays for +7.1% free cash flow growth a year for a decade; the business has delivered +14% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 8.55
- EV / salestoday's price, trailing year to Jun 30, 2026
- 6.09
- Healthcare median P/E503 names
- 27.9
- Drug Manufacturers - General median P/E16 names
- 40.0
- Free cash flow, trailing twelve months
- $16.1B
- Market capitalisation2.47 billion shares, counted Jul 31, 2026
- $358.4B
- 3-year revenue growth
- +4.5%
- 3-year free cash flow growth
- +14%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 115× today against a 22.4× median |
| 52-week range | $80.61 – $156.44 |
| Today | $145.27 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, General
The closest names by size in the same industry